secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001104659-22-105577
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Incyte elects Susanne Schaffert, former Novartis Oncology President, to board
-----------------------------------------------------------------------------

- Effective Oct 1, 2022, board increased to nine members, elected Susanne Schaffert.
- Dr. Schaffert spent 26 years at Novartis, most recently President of Novartis Oncology (Jan 2019–Apr 2022).
- She will serve as a non-employee director and receive standard cash/equity compensation.
- No arrangement, family relationship, or reportable transaction exists with Dr. Schaffert.
- She also serves on the board of Rubius Therapeutics, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000110465922105577/0001104659-22-105577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000110465922105577/tm2227007d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-105577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer